Worst case: $50 mill upfront, but commitment to meet all the costs of the Phase 3. $250 m on FDA approval, 10% royalties
Best case: More upfront, additional commitments to fully fund manufacturing and toxicity etc and European and other non-US approval applications/negotiations – leaving Neuren free to spend any upfront, milestone and royalties on other indications etc
What will the deal be like? Head vs heart, page-2
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.04 |
Change
-1.235(6.09%) |
Mkt cap ! $2.438B | |||
| Open | High | Low | Value | Volume |
| $20.40 | $20.50 | $18.92 | $12.76M | 657.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 245 | $19.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.04 | 637 | 8 |
View Market Depth
| Last trade - 14.51pm 04/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.01 |
Change
-1.235 ( 6.63 %) |
||||
| Open | High | Low | Volume | ||
| $20.39 | $20.46 | $18.83 | 251064 | ||
| Last updated 15.08pm 04/06/2024 ? | |||||
| NEU (ASX) Chart |